Analyst Serge Belanger from Needham maintained a Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report) and keeping the price target at $66.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Serge Belanger has given his Buy rating due to a combination of factors surrounding MoonLake Immunotherapeutics. The company is approaching a significant phase with upcoming data releases that could be transformative, particularly the anticipated results from the phase 3 VELA program expected in the third quarter of 2025. Additionally, there are key phase 2 data readouts for other programs, such as PPP and axSpA, expected later in the year, which could further bolster the company’s prospects.
MoonLake Immunotherapeutics is also in a strong financial position, having ended the first quarter of 2025 with approximately $480 million in cash, providing a financial runway into 2028. This solid financial footing, combined with the potential positive outcomes from the upcoming data releases, underpins the Buy rating and the price target of $66 set by Serge Belanger.
According to TipRanks, Belanger is a 3-star analyst with an average return of 0.8% and a 39.80% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Cytokinetics, and Esperion.
In another report released today, Wedbush also reiterated a Buy rating on the stock with a $80.00 price target.